Table 2 Treatment characteristics. Percentage relative to the total at the top row are presented in brackets. Chi-square contingency analysis was performed where indicated. Statistically significant results are highlighted in italic and an asterisk
All patients | Extensive Disease | Stage IV | |||||||
|---|---|---|---|---|---|---|---|---|---|
>4 cycles | 4 cycles | p value | >4 cycles | 4 cycles | p value | >4 cycles | 4 cycles | p value | |
Total N | 93 | 578 | 81 | 402 | 69 | 241 | |||
1st Line Chemotherapy, n (%) | 0.148 | 0.557 | 0.689 | ||||||
Cisplatin Etoposide | 2 (2.2) | 37 (6.4) | 2 (2.5) | 20 (5) | 1 (1.4) | 8 (3.3) | |||
Carboplatin Etoposide | 91 (97.8) | 541 (93.6) | 79 (97.5) | 382 (95) | 68 (98.6) | 233 (96.7) | |||
Cycle Number, n (%) | |||||||||
4 cycles | – | 578 (100) | – | 402 (100) | – | 241 (100) | |||
5 cycles | 13 (14) | – | 13 (16) | – | 11 (15.9) | – | |||
6 cycles | 80 (86) | – | 68 (84) | – | 58 (84.1) | – | |||
Average Cycles | 5.9 | 4 | 5.8 | 4 | 5.8 | 4 | |||
Response, n (%) | 0.461 | 0.9807 | 0.538 | ||||||
Progression | 3 (3.2) | 13 (2.2) | 3 (3.7) | 12 (3) | 2 (2.9) | 8 (3.3) | |||
Stable Disease | 12 (12.9) | 53 (9.2) | 11 (13.6) | 37 (9.2) | 10 (14.5) | 25 (10.4) | |||
Partial Response | 57 (61.3) | 412 (71.3) | 51 (63) | 288 (71.6) | 44 (63.8) | 74 (72.2) | |||
Complete Response | 21 (22.6) | 100 (17.3) | 16 (18.9) | 62 (15.4) | 13 (18.8) | 34 (14.1) | |||
Radiotherapy to lung, n (%) | 43 (46.2) | 254 (43.9) | 0.736 | 35 (43.2) | 146 (36.3) | 0.259 | 27 (39.1) | 61 (25.3) | 0.033* |
PCI, n (%) | 37 (39.8) | 240 (41.5) | 0.821 | 29 (35.8) | 156 (38.8) | 0.707 | 24 (34.8) | 96 (39.8) | 0.486 |
2nd line Chemotherapy, n (%) | 17 (18.3) | 167 (28.9) | 0.034* | 17 (21) | 108 (26.9) | 0.271 | 16 (23.2) | 62 (25.7) | 0.754 |
CarboEtop | 7 (7.5) | 88 (15.2) | 0.804 | 7 (8.6) | 47 (11.7) | 0.796 | 6 (8.7) | 29 (12) | 1.000 |
Topotecan | 4 (4.3) | 15 (2.6) | 4 (4.9) | 5 (1.2) | 4 (5.8) | 4 (1.7) | |||
CAV | 6 (6.5) | 62 (10.7) | 6 (7.4) | 42 (10.4) | 6 (8.7) | 28 (11.6) | |||
3rd line Chemotherapy, n (%) | 4 (4.3) | 26 (4.5) | 4 (4.9) | 18 (4.5) | 4 (5.8) | 9 (3.7) | |||